Enable Injections, Inc., a Cincinnati, OH-based company developing and manufacturing the enFuse platform of investigational wearable drug delivery systems, raised $215m in Series C financing.
The round was led by Magnetar Capital with participation from new institutional investments from GCM Grosvenor, Squarepoint Capital, Woody Creek Capital Partners, and existing investors Cincinnati Children’s Hospital Medical Center, CincyTech, Cintrifuse, and Ohio Innovation Fund.
Led by Mike Hooven, President and CEO, Enable Injections is an investigational-stage company developing and manufacturing on-body subcutaneous drug delivery systems designed to improve the patient experience, and advance healthcare system value and economics. Its body-worn enFuse® drug delivery platform utilizes standard container closure systems to deliver high-volume pharmaceutical and biologic therapeutics.
The company intends to use the funds to grow the enFuse platform globally.
FinSMEs
29/01/2022